Table 2:
Individual patient responses
| Patient information | DL | Time to progression (weeks) |
Best clinical response (Δ target lesions from baseline) |
|---|---|---|---|
| KRAS mutation | |||
| MSS colorectal cancer | 1 | 12 | PR* at 6 wk (−38%) |
| MSS colorectal cancer | 1 | 26 | SD at 12 wk (−4%) |
| Appendiceal cancer | 3 | 6 | PD at 6 wk (+6% + new) |
| Pancreatic cancer | 3 | 18 | SD at 6 wk (−20%) |
| Appendiceal cancer on capecitabine + bevacizumab | 3 | 80+ | SD at 12 wk (−8%) |
| MSS colorectal cancer | 3 | 82+ | PR at 82 wk (−30.6%) |
| KRAS wildtype | |||
| MSS colorectal cancer | 2 | 6 | PD at 6 wk (+23%) |
| MSS colorectal cancer | 2 | 6 | PD at 6 wk (+7% + new) |
| MSS colorectal cancer | 2 | 18 | SD at 6 wk (+11%) |
| MSS colorectal cancer | 3 | 6 | PD at 6 wk (+27%) |
| KRAS unknown or not tested | |||
| Endometrial cancer | 1 | 6 | PD at 6 wk (+13%) |
| Salivary gland cancer | 3 | 12+ | SD at 12 wk (−2%)** |
PR*, unconfirmed partial response; + ongoing treatment on trial; DL, dose level (DL1 = 1 MVA-BN-CV301 injection, DL2 = 2 MVA-BN-CV301 injections, DL3 = 4 MVA-BN-CV301 injections); MSS, microsatellite stable; SD, stable disease; PD, progressive disease; PR, partial response; wk, week; new, new lesion; **tumor resected at 13 weeks on trial. Patient remained on trial with no measurable disease but at high risk of recurrence.